Only one patient of our cohort with FLT3‐ITD positive disease received a targeted therapy with gilteritinib in combination with radiotherapy at the time of IEM‐AML relapse, achieving CR before undergoing transplantation (Supporting Information S1: Figure S6). The gene discussed is FLT3; the disease is acute myeloid leukemia.